PLK1 and ovarian carcinoma: In combination with other inhibitors, proTAME was shown to be efficient in overcoming resistance caused by the hyperphosphorylation of CDH1 in glioblastoma cells [9], polo-like kinase 1 (PLK1)-based drug resistance in ovarian cancer cells [10] and CDC20-based resistance in diffuse large B-cell lymphoma [11].